A study of ATI-50002 for the oral treatment of patchy alopecia areata

Trial Profile

A study of ATI-50002 for the oral treatment of patchy alopecia areata

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs ATI 50002 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2017 According to an Aclaris Therapeutics media release, the company plans to submit an investigational new drug (IND) application mid-2017.
    • 16 Nov 2016 New trial record
    • 03 Nov 2016 According to an Aclaris Therapeutics media release, the company plans to submit an investigational new drug (IND) application and commence clinical trials for in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top